| |
Fig. 5. (A) Inhibition of translation by an ADMP2 antisense morpholino oligonucleotide. Western blot of proteins extracted from stage 14 embryos that have been injected separately with 100 pg of RNA encoding an ADMP2/GFP fusion protein and either 10 ng of a control (c-MO) or antisense ADMP2 morpholino oligonucleotide (A-MO). Shown is the result of immunoblotting using an anti-GFP antibody and an anti-alpha-tubulin antibody (loading control). (B–G) Loss-of-function analysis of ADMP2. Control embryos (B, C, D), and embryos (E, F, G) injected with an antisense ADMP2 morpholino oligonucleotide (A-MO) probed for expression of a somite marker, XmyoD (B, E), a pronephros marker, Xlim1 (C, F) or a lateral plate marker, Xnr1 (D, G). (B, E) Stage 14 embryos. Anterior is to the left. Dorsal views. (C, D, F, G) Stage 24 embryos. Lateral views. Anterior to the left. |
